Updated Oct 14, 5:24 AM ET
BioXcel is awaiting court approval of a sale to Teva after receiving no competing qualified bids, according to its October 13, 2026 auction-cancellation notice Dkt. 232. The debtors cancelled the October 14 auction and will seek sale approval at the October 21 hearing, the next material step in the sale process.
Sale hearing10:00 AM ETDkt. 13Motion For Sale of Property Free and Clear of Liens(FEE) - Motion of the Debtors for an Order (I) Approving Bidding Procedures for the Sale of the Debtors' Assets, (II) Approving the Debtors' Entry into the Stalking Horse APA and Granting Bid Protections, (III) Approving Assumption and Assignment Procedures, (IV) Scheduling an Auction and Sale Hearing and Approving Forms and Manner of Notice Thereof, and (V) Granting Certain Related Relief Fee Amount $199 Filed by BioXcel Therapeutics, Inc.. (Attachments: # (1) Exhibit A # (2) Exhibit B # (3) Exhibit C) (Kochenash, Jared)
in 6 daysSearch available documents for this case. Full docket access requires Pro.
Open case researchBioXcel Files Chapter 11 With Teva Bid of $57.5M Plus Milestones ·
Case facts and filing dates come from court records.